



Published in final edited form as:

J Med Chem. 2010 January 14; 53(1): 471–480. doi:10.1021/jm901432g.

Human P2Y₁₄ Receptor Agonists: Truncation of the Hexose Moiety of Uridine-5'-Diphosphoglucose and its Replacement with Alkyl and Aryl Groups

Arijit Das^a, Hyojin Ko^a, Lauren E. Burianek^b, Matthew O. Barrett^b, T. Kendall Harden^b, and Kenneth A. Jacobson^{a,*}

^a Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

^b Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.

Abstract

Uridine-5'-diphosphoglucose (UDPG) activates the P2Y₁₄ receptor, a neuroimmune system GPCR. P2Y₁₄ receptor tolerates glucose substitution with small alkyl or aryl groups or its truncation to uridine-5'-diphosphate (UDP), a full agonist human P2Y₁₄ receptor expressed in HEK-293 cells. 2-Thiouracil derivatives displayed selectivity for activation of the human P2Y₁₄ vs. the P2Y₆ receptor, such as 2-thio-UDP **4** (EC₅₀ 1.92 nM at P2Y₁₄, 224-fold selectivity vs. P2Y₆) and its β-propyloxy ester **18**. EC₅₀ of β-methyl ester of UDP and its 2-thio analogue were 2730 and 56 nM, respectively. β-t-Butyl ester of **4** was 11-fold more potent than UDPG, but β-aryloxy or larger, branched β-alkyl esters, such as cyclohexyl, were less potent. Ribose replacement of UDP with a rigid North or South methanocarba (bicyclo[3.1.0]hexane) group abolished P2Y₁₄ receptor agonist activity. α,β-Methylene and difluoromethylene groups were well tolerated at the P2Y₁₄ receptor and are expected to provide enhanced stability in biological systems. α,β-Methylene-2-thio-UDP **11** (EC₅₀ 0.92 nM) was 2160-fold selective versus P2Y₆. Thus, these nucleotides and their congeners may serve as important pharmacological probes for the detection and characterization of the P2Y₁₄ receptor.

Keywords

G protein-coupled receptor; nucleotides; pyrimidines; phospholipase C; carbohydrates; uracil

Introduction

Purine and pyrimidine mononucleotides and dinucleotides have a role as extracellular signaling molecules, in addition to their diverse intracellular roles.¹ The P2Y family of G protein-coupled receptors (GPCRs) responds to various extracellular nucleotides to induce intracellular signaling cascades.²⁻⁴ The P2Y₁₄ receptor was identified initially as an orphan GPCR activated by uridine-5'-diphosphoglucose (UDPG **1**; Chart 1) and other endogenous UDP-sugars. This Gi-coupled receptor is expressed in the brain and in dendritic cells,⁵ although no functional

* **Corresponding author:** Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. kajacobs@helix.nih.gov; tel. 301-496-9024, FAX 301-480-8422..

Supporting Information Available: NMR spectral data and HPLC traces of selected nucleotide derivatives are included. This material is available free of charge via the Internet at <http://pubs.acs.org>.

role has yet been clearly assigned in these tissues. The P2Y₁₄ receptor also is expressed in the placenta, adipose tissue, stomach, intestine, brain, spleen, thymus, lung, and heart.¹ Thus, the P2Y₁₄ receptor is of potential therapeutic interest for modulation of the immune system,⁷ as well as treatment of pain,⁸ diabetes,⁹ cystic fibrosis, and other pulmonary diseases.^{10,11}

A current goal of our research is to identify and apply potent, selective, and stable P2Y₁₄ receptor ligands to define the physiological role(s) of this receptor.¹²⁻¹⁴ Although the P2Y₁₄ receptor initially was identified as a UDP-sugar-activated GPCR, we recently discovered that UDP is at least as potent as UDP-glucose and other nucleotide sugars for activation of this receptor.¹⁴ Thus, it is perhaps not surprising that our recent detailed SAR (structure activity relationship) analyses with synthetic analogues of UDPG^{12,13} revealed that the glucose moiety is the least restricted region of the structure for substitutions that maintain P2Y₁₄ receptor agonist potency. This realization, together with conclusions made from our recent SAR study of UDP analogues at the P2Y₆ receptor,¹⁵ suggests that β -phosphate-substitution in a new series of UDP analogues might favor activation of the P2Y₁₄ receptor. Therefore, with the ultimate goal of identifying highly selective ligands for the P2Y₁₄ and P2Y₆ receptors, we have synthesized a new series of β -phosphate-substituted analogues of UDP and compared the potencies of these novel molecules as well as a number of previously prepared uracil nucleotide analogues at the human P2Y₁₄ and P2Y₆ receptors. Although the glucose moiety of UDPG was suggested to interact with multiple H-bonding and/or charged residues within the putative binding site of the P2Y₁₄ receptor, its deletion or substitution with smaller phosphoester groups was tolerated at this receptor. Simple alkyl esters at this position and analogues of UDP displayed highly potent agonist activity at the P2Y₁₄ receptor. The effects of these modifications to preserve and enhance potency at the P2Y₁₄ receptor were additive with the previously identified potency enhancing effect of 2-thio substitution of the uracil moiety, achieving in some cases nanomolar and subnanomolar potency. Importantly, a number of these new UDP analogues exhibit high selectivity for activation of the P2Y₁₄ receptor over the P2Y₆ receptor.

Results

Chemical Synthesis

The principal objective of this study was to structurally simplify the distal end of uracil nucleotide sugars known to activate the hP2Y₁₄ receptor and to combine potency-enhancing modifications. By removing the glucose moiety of UDPG **1**, this agonist is converted into UDP **3**, which we recently discovered is a highly potent agonist of the hP2Y₁₄ receptor.^{14,16} The activities of analogues of **1** modified on the glucose moiety have been explored, but intermediate structures and truncated analogues related to UDP have not been systematically examined. We also were searching for leads for UDP analogues that might provide selectivity at the P2Y₁₄ receptor over the P2Y₆ receptor.

Simple ester and 5'-diphosphate analogues of the hP2Y₁₄ receptor agonist UDPG **1** and its 2-thio derivative **2** were synthesized (Table 1). The only modifications of the nucleobase included were thiocarbonyl or methoxyamino substitution of carbonyl groups of the uracil moiety, which were studied previously in P2Y₁₄ receptor recognition.¹² Several of the analogues of UDP **3** studied here were reported in studies of SAR at the P2Y₆ receptor.^{15,17,18} All of the nucleotide analogues were prepared in their ammonium or triethylammonium salt form according to the methods shown in Schemes 1 – 3 and tested in functional assays of the hP2Y₁₄ and hP2Y₆ receptors (Table 1).

The uridine-5'-diphospho alkyl or aryl derivatives were obtained by the following methods. The corresponding alkyl or aryl monophosphate analogues were treated successively with cation-exchange resin and tributylamine. To the solution of the alkyl or aryl monophosphate

tributylammonium salt in DMF, commercially available uridine 5'-monophosphate morpholidate 4-morpholine-*N,N*-dicyclohexylcarboxamidate salt was added to form uridine-5'-diphospho- β -ester analogues (**6**, **14**, **19** – **20**, **22** – **24**, and **26** – **30**) in a condensation reaction as shown in Scheme 1. 2-Thio UDP **4** and 4-thio UDP **5** were synthesized by using the previously reported procedure.¹⁷ (N)-Methanocarba-UDP **8** and (S)-methanocarba-UDP **9** were synthesized using our previously reported procedures.^{15,19,20} α,β -Methylene-UDP **10** and α,β -difluoromethylene-UDP **12** were also prepared using our recently published procedures or modifications thereof. 2-Thio- α,β -methylene-UDP **11** was prepared by the DCC coupling of 2-thiouridine with methylenediphosphonic acid (Scheme 3).¹⁸ Compound **7** and **13** were synthesized by using a recently developed procedure.¹⁵

For the preparation of the 2- or 4-thiocarbonyl β -alkyldiphosphate esters (**15** – **18**, **21** and **25**), we either synthesized the alkylmonophosphate (**42** – **44**)²¹ or obtained the commercially available alkylmonophosphates (**41**, **45**). The monophosphates were transformed to the corresponding tributylammonium salts and were then activated with 1,1'-carbonyldiimidazole in DMF for 5 h at room temperature followed by quenching of this reagent with methanol. After removing the solvent, the residue was dissolved in DMF, and 2-thio or 4-thiouridine 5'-monophosphate tributylammonium salt was added to obtain compounds **15** – **18**, **21**, and **25** as shown in Scheme 2. All the nucleotide analogues were characterized using HPLC, nuclear magnetic resonance (¹H NMR, ³¹P NMR), and high-resolution mass spectrometry.

Quantification of Pharmacological Activity

Inhibition of adenylyl cyclase was quantified in HEK-293 cells stably expressing the hP2Y₁₄ receptor. This cell line, as well as a P2Y₁₄ receptor-expressing Chinese hamster ovary (CHO) cell line and a P2Y₁₄ receptor-expressing C6 rat glioma cell line that we recently developed, provides a physiologically relevant test system since receptor-promoted responses mediated through a natively expressed heterotrimeric G protein (Gi) and its natively expressed effector protein (adenylyl cyclase) are quantified.¹⁴ We conclude that this system is much preferable to assay methods, employed by us and others, which utilized COS-7 cells transiently over-expressing the P2Y₁₄ receptor with an engineered G protein, *G α -q/i* protein (*G α _{q/i5}*), that allows coupling of Gi-coupled receptors to activation of phospholipase C (PLC), resulting in inositol lipid hydrolysis.²²⁻²⁴

Although UDPG **1** is usually thought of as a specific agonist of the P2Y₁₄ receptor, it also was found to activate the P2Y₂ receptor (EC₅₀ ~ 10 μ M).¹³ We now report EC₅₀ values for **1** of 0.40 μ M and 16 μ M at the P2Y₁₄ and P2Y₆ receptor, respectively (Table 1). Therefore, although selective for the P2Y₁₄ receptor, UDPG also activates other P2Y receptors. Thus, more potent and selective agonists, preferably with a simplified chemical structure, are needed as pharmacological probes of the P2Y₁₄ receptor.

UDP **3** and its 4-thio derivative **5** were moderately potent agonists at the hP2Y₁₄ receptor. One of the most potent P2Y₁₄ receptor agonists in the current set of nucleotides was the 2-thio derivative **4** of UDP, which displayed an EC₅₀ value of 1.92 nM. Compound **4** was 83-fold more potent than **3** as a P2Y₁₄ receptor agonist and 230-fold selective for the P2Y₁₄ receptor in comparison to the P2Y₆ receptor. Replacement of a terminal negatively charged oxygen of **3** with an uncharged methyl group in the phosphonate derivative **6** resulted in a molecule with similarly weak potencies at the two receptors. The *N*⁴-methoxy cytidine derivative **7** was 20-fold less potent than **3** at the P2Y₁₄ receptor and consequently displayed selectivity for the P2Y₆ receptor, at which its high potency has been described.¹⁵ This finding is consistent with the reported weak P2Y₁₄ receptor activity of the corresponding *N*⁴-methoxy cytidine analogue of UDPG.¹³

Replacement of a ribose moiety of various P2Y receptor agonists with a sterically constrained bicyclic ring has been used to establish the receptor-preferred conformation. Neither of the conformationally constrained methanocarba analogues **8** (North, N) and **9** (South, S) of UDP **3** was active at the P2Y₁₄ receptor. Consistent with these findings with analogues of **3**, we have already established that the corresponding (N) and (S) methanocarba analogues of UDPG were both inactive at the P2Y₁₄ receptor.¹³

The introduction of carbon-bridged substitutions of the phosphate moieties of P2 agonists has led to greater stability in biological systems due to the inability of ectonucleotidases to cleave these groups.^{1,27} Replacement of the bridging oxygen of the diphosphate group of UDP with a methylene **10** or difluoromethylene **12** group was well tolerated at the P2Y₁₄ receptor, resulting in high potency with EC₅₀ values of 11 and 63 nM, respectively. Indeed, the α,β -difluoromethylene analogue **12** was >2000-fold selective for the P2Y₁₄ receptor in comparison to the P2Y₆ receptor, at which it was inactive at the concentrations tested. Combining a carbon bridge with a known potency-enhancing uracil modification in 2-thio- α,β -methylene analogue **11** resulted in unprecedented potency at the hP2Y₁₄ receptor with an EC₅₀ value of 0.92 nM. The selectivity of **11** in comparison to the hP2Y₆ receptor was 2160-fold. Combining the α,β -difluoromethylene and 5-iodo modifications in **13** maintained equipotency to UDP **3** at the P2Y₁₄ receptor, which stands in contrast with the inactivity of 5-iodo-UDPG and suggests non-identical modes of uracil binding to the receptor between the two series.¹² However, **13** was not selective for the P2Y₁₄ receptor when compared to the P2Y₆ receptor.

The native agonist **1** is a β -ester of the diphosphate moiety, which prompted us to explore the potency of structurally simpler β -esters at the P2Y₁₄ receptor. Since compound **14**, modified with a methyl ester group instead of glucose, weakly activated the P2Y₁₄ receptor and was inactive at the P2Y₆ receptor, this methyl ester was combined with other modifications to probe the effects on biological activity. The combination with the 2-thio modification in compound **15** increased potency by 42-fold. Thus, compound **15** was >180-fold selective for the P2Y₁₄ receptor. The 4-thio modification in methyl ester **16** abolished and greatly reduced potency in comparison to **15** at the P2Y₁₄ and P2Y₆ receptors, respectively.

In the 2-thio series, homologation of the alkyl ester group of **15** was tolerated at the P2Y₁₄ receptor, with the ethyl **17** and propyl **18** derivatives both displaying EC₅₀ values of ~40 nM and >200-fold selectivity in comparison to the P2Y₆ receptor. A 2-cyanoethyl group in **19** was poorly tolerated at the P2Y₁₄ receptor. Substitution of the β -methyl ester with a *t*-butyl ester group in **25** produced an equipotent agonist, which was 8-fold more potent than the corresponding 2-oxo analogue **24**. The β -*t*-butyloxy ester of 2-thio-UDP **25** was 11-fold more potent than UDPG. Introduction of a glyceryl moiety esterified through the 2-hydroxyl group in **23** did not diminish the potency of **3**, but an isomeric glyceryl ester **22** was 10-fold less potent than **3**.

Alkynyl ester derivatives **20** (2-oxo) or **21** (2-thio) were either 2-fold less potent or 16-fold more potent, respectively, than **3** at the P2Y₁₄ receptor. Compound **21** was >900-fold selective in comparison to the P2Y₆ receptor.

β -Aryloxy and cycloalkyloxy esters **26** – **30** of UDP were found to only weakly activate the receptor, in the order of potency phenyl > 4-nitrophenyl > 3-chloro- and 4-methoxyphenyl > cyclohexyl.

Discussion

In the present study, we have further expanded the range of potent P2Y₁₄ receptor ligands through a systematic exploration of the SAR of structurally simple analogues at this receptor, particularly with respect to substitution of the glucose moiety with diverse alkyl moieties. We

have found that the introduction of α,β -methylene and difluoromethylene groups is well tolerated at the P2Y₁₄ receptor. These carbon-bridged nucleotides, including α,β -methylene-UDP with an EC₅₀ value of 11 nM, are expected to display greater stability in biological systems. Methylene-bridged nucleotides tend to have increased stability by impeding breakdown by ecto-nucleotidases present on the cell surface,²⁷⁻²⁹ and thus, these carbon-bridged diphosphate analogues have good potential for in vivo applications.

The 2-thio modification, but not the 4-thio modification of the uracil ring, tended to increase potency and selectivity at the P2Y₁₄ receptor in comparison to the P2Y₆ receptor. The most selective compounds (fold selectivity for P2Y₁₄ in comparison to P2Y₆) in the present study were UDP analogues **4** (233), **11** (2160), **12** (>150), **15** (>180), **17** (>250), **18** (230), and **21** (>900). The most potent of these were 2-thio-UDP **4** and α,β -methylene-2-thio-UDP **11**. Compound **4** had a high potency at the P2Y₁₄ receptor, with an EC₅₀ value of 1.92 nM, and the corresponding α,β -methylene analogue **11** was even twice as potent. Although it is a less potent P2Y₁₄ receptor agonist, difluoromethylene-UDP **12** did not activate the P2Y₆ receptor at the concentrations of analogue tested. Other compounds that displayed lesser selectivity for the P2Y₁₄ receptor were (fold): **25** (64), **23** (59), **24** (43), and **10** (31). Thus, the 2-thio derivatives **4**, **11**, and their congeners may serve as important pharmacological probes for the detection and characterization of the P2Y₁₄ receptor.

It is now clear that the glucose moiety of **1** is not required for activation of the P2Y₁₄ receptor; although when it is present, there is a SAR pattern related to interaction of specific functionality of this hexose moiety with the receptor.^{13,26} We conclude here that UDP and its analogues are potent full agonists of the human P2Y₁₄ receptor, consistent with our recent pharmacological studies of this receptor stably expressed in three different cell lines that utilized native G_i proteins for signal transduction.¹⁴ This finding contradicts with the original work of Fricks et al. who reported that UDP is a partial agonist/competitive antagonist of the human P2Y₁₄ receptor, while acting as a full agonist at the rat P2Y₁₄ receptor.¹⁶ However, the latter study quantified activity of a recombinant P2Y₁₄ receptor transiently coexpressed with an unnatural chimeric G protein, Gaq/i that couples Gi-activating receptors to activation of PLC- β isozymes. It was suggested that this system favors “a conformation of the P2Y₁₄-R..., which results in ligand binding selectivities and agonist activities that are not altogether consistent with activities of the receptor obtained when coupled to its cognate heterotrimeric G protein.” Thus, the efficacy of UDP appears to be a function of the G protein signaling system activated by the receptor.

In conclusion, we have identified new analogues of UDP and its simple esters that display enhanced potency and selectivity for the P2Y₁₄ receptor and which promise to be useful as pharmacological tools to distinguish the effects of uracil nucleotides acting at P2Y₁₄ versus P2Y₆ receptors. The nanomolar potency achieved in this series is until now unprecedented for small molecular ligands of the P2Y₁₄ receptor. It is now possible to examine these potent agonists on human cells expressing an endogenous P2Y₁₄ receptor to aid in delineating a role for this receptor.

Experimental Section

Chemical Synthesis

¹H NMR spectra were obtained with a Varian Gemini 300 spectrometer using D₂O as a solvent. The chemical shifts are expressed as relative ppm from HOD (4.80 ppm). ³¹P NMR spectra were recorded at room temperature by use of a Varian XL 300 spectrometer (121.42 MHz); orthophosphoric acid (85%) was used as an external standard.

Purity and extent of reaction of nucleotide derivatives was checked using a Hewlett–Packard 1100 HPLC equipped with a Zorbax Eclipse 5 μ m XDB-C18 analytical column (250 \times 4.6 mm; Agilent Technologies Inc, Palo Alto, CA), linear gradient solvent system: 5 mM TBAP (tetrabutylammonium dihydrogenphosphate)-CH₃CN from 80:20 to 40:60 in 20 min, with a flow rate of 1 mL/min (System A), or Zorbax SB-Aq 5 μ m analytical column (50 \times 4.6 mm; Agilent Technologies Inc, Palo Alto, CA). Mobile phase: linear gradient solvent system: 5 mM TBAP (tetrabutylammonium dihydrogenphosphate)-CH₃CN from 80:20 to 40:60 in 13 min; the flow rate was 0.5 mL/min (System B). Peaks were detected by UV absorption (254 nm) with a diode array detector.

Purification of the nucleotide analogues for biological testing was carried out on (diethylamino) ethyl (DEAE)-A25 Sephadex columns with a linear gradient (0.01–0.5 M) of 0.5 M ammonium bicarbonate as the mobile phase. Some of the compounds were additionally purified by HPLC with a Luna 5- μ m RP-C18(2) semipreparative column (250 \times 10.0 mm; Phenomenex, Torrance, CA) and using a linear gradient solvent system of 10 mM TEAA (triethylammonium acetate)-CH₃CN from 100:0 to 95:5 (or up to 99:1 to 90:10) in 30 min, with a flow rate of 2 mL/min. The tested nucleotide derivatives were confirmed by HPLC to possess a \geq 95% purity. Compounds purified by HPLC were isolated as the triethylammonium salts. Compounds **41** and **45**, other reagents, and solvents were purchased from Sigma-Aldrich (St. Louis, MO).

General Procedure for the Preparation of Uridine 5'-Diphosphoglucose Analogues

The appropriate alkyl or aryl monophosphate was first converted to its tributylammonium salt form by the treatment with ion-exchange resin (DOWEX 50WX2-200 (H)), which upon acidification of the supernatant was followed by addition of tributylamine until a basic pH was reached. The aqueous solvent was removed by lyophilization, and the residue was used without further purification. A solution in DMF (1.5 mL) of uridine 5'-monophosphate morpholidate 4-morpholine-*N,N*-dicyclohexylcarboxamidinium salt (20 mg, 0.029 mmol) and the corresponding monophosphate (0.035 mmol, tributylammonium salt) was stirred at room temperature for 2 days. After that the solvent was removed and the residue was purified by ion-exchange column chromatography using a Sephadex-DEAE A-25 resin (with a linear gradient (0.01-0.5 M) of 0.5 M ammonium bicarbonate as the mobile phase) to provide the corresponding nucleotide as the ammonium salt. Some of the uridine 5'-diphosphoglucose analogues were additionally purified by HPLC as described above.

Diphosphoric acid 1- β -methyl (C-P) 2-(uridine-5'-yl)ester, triethylammonium salt (6)

Compound **6** (4.0 mg, 23%) was obtained as a white solid following the general procedure. ¹H NMR (D₂O) δ 7.96 (d, *J* = 8.1 Hz, 1H), 6.00 (d, *J* = 4.8 Hz, 1H), 5.97 (d, *J* = 7.8 Hz, 1H), 4.38 (m, 2H), 4.29 (m, 1H), 4.21 (m, 2H), 1.46 (d, *J* = 16.8 Hz, 3H); ³¹P NMR (D₂O) δ 17.82 (d, *J* = 23.9 Hz), -11.06 (d, *J* = 23.8 Hz); HRMS-EI found 401.0158 (M - H⁺)⁻. C₁₀H₁₅N₂O₁₁P₂ requires 401.0151; purity > 98% by HPLC. (System A: 13.3 min).

Diphosphoric acid 1- β -methyl ester 2-(uridine-5'-yl)ester, ammonium salt (14)

Compound **14** (3.9 mg, 30%) was obtained as a white solid following the general procedure. ¹H NMR (D₂O) δ 7.97 (d, *J* = 8.1 Hz, 1H), 6.01 (dd, *J* = 3.6, 1.2 Hz, 1H), 5.97 (d, *J* = 8.1 Hz, 1H), 4.38 (m, 2H), 4.29 (m, 1H), 4.20 (m, 2H), 3.66 (d, *J* = 11.4 Hz, 3H); ³¹P NMR (D₂O) δ -9.22 (d, *J* = 21.4 Hz), -11.03 (d, *J* = 21.4 Hz); HRMS-EI found 417.0087 (M - H⁺)⁻. C₁₀H₁₅N₂O₁₂P₂ requires 417.0100; purity > 98% by HPLC. (System A: 11.3 min).

Diphosphoric acid 1- β -(2-cyanoethyl)ester 2-(uridine-5'-yl)ester, ammonium salt (19)

Compound **19** (3.7 mg, 26%) was obtained as a white solid following the general procedure. ¹H NMR (D₂O) δ 7.99 (d, *J* = 8.4 Hz, 1H), 5.99 (m, 2H), 4.89 (m, 2H), 4.26 (m,

3H), 4.16 (dd, $J = 12.9, 6.0$ Hz, 2H), 2.87 (t, $J = 6.07$ Hz, 2H); ^{31}P NMR (D_2O) $\delta -11.18$ (dd, $J = 42.8, 21.4$ Hz); HRMS-EI found 456.0212 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{12}\text{H}_{16}\text{N}_3\text{O}_{12}\text{P}_2$ requires 456.0209; purity > 98% by HPLC. (System A: 12.8 min).

Diphosphoric acid 1- β -(3-butynyl)ester 2-(uridine-5'-yl)ester, triethylammonium salt (20)

Compound **20** (5.31 mg, 28%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 7.88 (d, $J = 8.1$ Hz, 1H), 5.98 (m, 2H), 4.41 (m, 1H), 4.21 (m, 3H), 4.08 (m, 1H), 3.83 (m, 2H), 2.53 (m, 3H); ^{31}P NMR (D_2O) $\delta -9.61$ (d, $J = 16.5$ Hz), -11.2 (m), HRMS-EI found 455.0257 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{13}\text{H}_{17}\text{N}_2\text{O}_{12}\text{P}_2$ requires 455.0265; purity > 97% by HPLC. (System B: 6.89 min).

Diphosphoric acid 1- α -glycerol ester 2-(uridine-5'-yl)ester, ammonium salt (22)

Compound **22** (2.2 mg, 15%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 7.96 (d, $J = 8.4$ Hz, 1H), 5.60 (m, 2H), 4.40 (m, 2H), 4.26 (m, 3H), 3.99 (m, 3H), 3.68 (m, 2H); ^{31}P NMR (D_2O) $\delta -10.35$ (d, $J = 21.4$ Hz), -10.97 (d, $J = 20.8$ Hz); HRMS-EI found 477.0315 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{12}\text{H}_{19}\text{N}_2\text{O}_{14}\text{P}_2$ requires 477.0312; purity > 98% by HPLC. (System A: 13.6 min).

Diphosphoric acid 1- β -glycerol ester 2-(uridine-5'-yl)ester, triethylammonium salt (23)

Compound **23** (3.1 mg, 16%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 7.97 (d, $J = 7.8$ Hz, 1H), 6.01 (m, 1H), 5.98 (d, $J = 7.8$ Hz, 1H), 4.39 (m, 2H), 4.30 (m, 2H), 4.24 (m, 2H), 3.77 (m, 4H); ^{31}P NMR (D_2O) $\delta -10.89$ (dd, $J = 37.9, 21.4$ Hz); HRMS-EI found 477.0302 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{12}\text{H}_{19}\text{N}_2\text{O}_{14}\text{P}_2$ requires 477.0312; purity > 98% by HPLC. (System A: 11.2 min).

Diphosphoric acid 1- β -tert-butyl ester 2-(uridine-5'-yl)ester, ammonium salt (24)

Compound **24** (4.4 mg, 31%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 7.99 (d, $J = 7.8$ Hz, 1H), 5.99 (m, 2H), 4.39 (m, 2H), 4.29 (m, 1H), 4.24 (m, 2H), 1.44 (d, $J = 0.3$ Hz, 9H); ^{31}P NMR (D_2O) $\delta -11.51$ (d, $J = 21.4$ Hz), -14.73 (d, $J = 21.4$ Hz); HRMS-EI found 459.0565 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{13}\text{H}_{21}\text{N}_2\text{O}_{12}\text{P}_2$ requires 459.0570; purity > 98% by HPLC. (System A: 13.6 min).

Diphosphoric acid 1- β -cyclohexyl ester 2-(uridine-5'-yl)ester, ammonium salt (26)

Compound **26** (6.2 mg, 41%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 8.00 (d, $J = 8.4$ Hz, 1H), 6.00 (m, 2H), 4.40 (m, 2H), 4.30 (m, 1H), 4.24 (m, 2H), 4.20 (m, 1H), 1.97 (m, 2H), 1.72 (m, 2H), 1.50-1.10 (m, 6H); ^{31}P NMR (D_2O) $\delta -11.26$; HRMS-EI found 485.0719 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{15}\text{H}_{23}\text{N}_2\text{O}_{12}\text{P}_2$ requires 485.0726; purity > 98% by HPLC. (System A: 11.8 min).

Diphosphoric acid 1- β -phenyl ester 2-(uridine-5'-yl)ester, ammonium salt (27)

Compound **27** (4.7 mg, 32%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 7.87 (d, $J = 8.4$ Hz, 1H), 7.36 (m, 2H), 7.19 (m, 3H), 5.93 (d, $J = 5.1$ Hz, 1H), 5.81 (d, $J = 8.4$ Hz, 1H), 4.30 (m, 1H), 4.25 (m, 2H), 4.20 (m, 1H), 4.15 (m, 1H); ^{31}P NMR (D_2O) $\delta -11.11$ (d, $J = 21.5$ Hz), -15.74 (d, $J = 20.8$ Hz); HRMS-EI found 479.0247 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_{12}\text{P}_2$ requires 479.0257; purity > 98% by HPLC. (System A: 13.1 min).

Diphosphoric acid 1- β -(4-nitrophenyl)ester 2-(uridine-5'-yl)ester, ammonium salt (28)

Compound **28** (6.1 mg, 38%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 8.21 (d, $J = 9.3$ Hz, 2H), δ 7.76 (d, $J = 7.83$ Hz, 1H), δ 7.37 (d,

$J = 9.0$ Hz, 2H), 5.92 (m, 1H), 5.69 (d, $J = 7.5$ Hz, 1H), 4.25 (m, 4H), 4.14 (m, 1H); ^{31}P NMR (D_2O) $\delta -11.15$ (d, $J = 20.8$ Hz), -17.12 (d, $J = 20.8$ Hz); HRMS-EI found 524.0110 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{15}\text{H}_{16}\text{N}_3\text{O}_{14}\text{P}_2$ requires 524.0108; purity > 98% by HPLC. (System A: 13.7 min).

Diphosphoric acid 1- β -(3-chlorophenyl)ester 2-(uridine-5'-yl)ester, ammonium salt (29)

Compound **29** (3.7 mg, 25%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 7.85(d, $J = 8.1$ Hz, 1H), 7.33 (m, 3H), 7.17 (m, 1H), 5.95 (d, $J = 4.2$ Hz, 1H), 5.76 (d, $J = 8.1$ Hz, 1H), 4.29 (m, 4H), 4.18 (m, 1H); ^{31}P NMR (D_2O) $\delta -11.04$ (d, $J = 21.3$ Hz), -16.18 (d, $J = 21.3$ Hz); HRMS-EI found 512.9867 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_{12}\text{ClP}_2$ requires 512.9854; purity > 98% by HPLC. (System B: 8.6 min).

Diphosphoric acid 1- β -(4-methoxyphenyl)ester 2-(uridine-5'-yl)ester, ammonium salt (30)

Compound **30** (3.3 mg, 21%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 7.82 (d, $J = 8.1$ Hz, 1H), 7.18 (d, $J = 8.7$ Hz, 2H), δ 6.93 (d, $J = 8.7$ Hz, 2H), 5.95 (d, $J = 4.8$ Hz, 1H), δ 5.77 (d, $J = 8.1$ Hz, 1H), 4.29 (m, 4H), 4.16 (m, 1H); ^{31}P NMR (D_2O) $\delta -11.04$ (d, $J = 21.3$ Hz), -15.37 (d, $J = 21.3$ Hz); HRMS-EI found 509.0362 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{16}\text{H}_{19}\text{N}_2\text{O}_{13}\text{P}_2$ requires 509.0353; purity > 98% by HPLC. (System B: 8.84 min).

General procedure for the preparation of diphosphoric acid 1-alkyl ester 2-(thio uridine-5'-yl)ester (15-18, 21, and 25)

Monophosphates (**42-44**) were prepared from the corresponding alcohols (**37-39**) using a published procedure,²¹ and the spectral data were consistent with the assigned structures.

Each of the prepared monophosphates (**42-44**)²¹ or commercially available monophosphates (**41**, **45**) was transformed to its tributylammonium salt by treatment with ion exchange resin followed by the addition of tributylamine. 1,1'-carbonyldiimidazole (10 mg, 0.06 mmol) was added to the alkyl monophosphate tributylammonium salts (0.017 mmol) (**41-45**) in DMF (1 mL). The reaction mixture was stirred at room temperature for 5 h. Methanol (1 mL) was added and stirring was continued at room temperature for an additional 1 h. After removal of the solvent, the residue was dried under high vacuum and dissolved in DMF (1.5 mL). 2-Thiouridine 5'-monophosphate tributylammonium salt (**34**)¹² (5.7 mg, 0.008 mmol) for **15**, **17**, **18**, **21**, and **25** or 4-thiouridine 5'-monophosphate tributylammonium salt (**35**)¹² (5.7 mg, 0.008 mmol) for **16** was added to the reaction mixture and it was stirred at room temperature for 2 d. After removal of the solvent, the residue was purified by the same method as general procedure using Sephadex-DEAE A-25 resin. Compounds **16** and **21** were further purified by HPLC to provide homogeneous products.

Diphosphoric acid 1- β -methyl ester 2-(2-thiouridine-5'-yl)ester, ammonium salt (15)

Compound **15** (0.82 mg, 22%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 8.15 (d, $J = 8.1$ Hz, 1H), 6.70 (d, $J = 3.6$ Hz, 1H), 6.24 (d, $J = 8.1$ Hz, 1H), 4.43 (m, 1H), 3.34 (m, 3H), 4.24 (m, 1H), 3.66 (d, $J = 11.7$ Hz, 3H); ^{31}P NMR (D_2O) $\delta -10.68$ (dd, $J = 21.5, 6.6$ Hz), -11.05 (d, $J = 21.4$ Hz); HRMS-EI found 432.9886 ($\text{M} - \text{H}^+$) $^-$. $\text{C}_{10}\text{H}_{15}\text{N}_2\text{O}_{11}\text{P}_2\text{S}$ requires 432.9872; purity > 98% by HPLC. (System A: 12.9 min).

Diphosphoric acid 1- β -methyl ester 2-(4-thiouridine-5'-yl)ester, triethyl ammonium salt (16)

Compound **16** (0.91 mg, 18%) was obtained as a white solid following the general procedure. ^1H NMR (D_2O) δ 7.9 (d, $J = 7.7$ Hz, 1H), 6.69 (d, $J = 4.3$ Hz, 1H), 5.99 (d, $J = 7.5$ Hz, 1H), 4.40 (m, 3H), 4.30 (m, 2H), 3.69 (m, 3H); ^{31}P NMR (D_2O) $\delta -10.83$ (d, $J = 21.3$, Hz), -11.12 (d, $J = 21.3$ Hz); HRMS-EI found 432.9884 ($\text{M} - \text{H}^+$) $^-$.

$C_{10}H_{15}N_2O_{11}P_2S$ requires 432.9872; purity > 98% by HPLC. (System B: 7.2 min in negative absorbance).

Diphosphoric acid 1- β -ethyl ester 2-(2-thiouridine-5'-yl)ester, ammonium salt (17)

Compound **17** (7.7 mg, 20%) was obtained as a white solid following the general procedure. 1H NMR (D_2O) δ 8.22 (d, J = 8.1 Hz, 1H), 6.72 (d, J = 3.0 Hz, 1H), 6.32 (d, J = 8.4 Hz, 1H), 4.49 (m, 1H), 3.39 (m, 3H), 4.29 (m, 1H), 4.09 (m, 2H), 1.33 (m, 3H); ^{31}P NMR (D_2O) δ -10.39 (t, J = 21.3, 42.7 Hz), -11.08 (d, J = 21.3 Hz); HRMS-EI found 447.0022 ($M - H^+$)⁻. $C_{11}H_{17}N_2O_{11}P_2S$ requires 447.0028; purity > 98% by HPLC. (System B: 7.09 min).

Diphosphoric acid 1- β -propyl ester 2-(2-thiouridine-5'-yl)ester, ammonium salt (18)

Compound **18** (0.91 mg, 23%) was obtained as a white solid following the general procedure. 1H NMR (D_2O) δ 8.21 (d, J = 8.4 Hz, 1H), 6.69 (d, J = 3.1 Hz, 1H), 6.28 (d, J = 8.4 Hz, 1H), 4.47 (m, 1H), 3.41 (m, 3H), 4.26 (m, 1H), 3.95 (m, 2H), 1.65 (m, 2H); 0.96 (m, 3H); ^{31}P NMR (D_2O) δ -10.68 (d, J = 21.5, 4.), -11.10 (d, J = 21.3 Hz); HRMS-EI found 461.0145 ($M - H^+$)⁻. $C_{12}H_{19}N_2O_{11}P_2S$ requires 461.0151; purity > 98% by HPLC. (System B: 7.4 min).

Diphosphoric acid 1- β -(3-butynyl) ester 2-(2-thiouridine-5'-yl)ester, triethylammonium salt (21)

Compound **21** (1.18 mg, 22%) was obtained as a white solid following the general procedure. 1H NMR (D_2O) δ 8.12 (d, J = 8.1 Hz, 1H), 6.79 (d, J = 3.1 Hz, 1H), 6.23 (d, J = 8.1 Hz, 1H), 4.43 (m, 1H), 4.35 (m, 1H), 4.10 (m, 3H), 3.89 (m, 2H), 2.54 (m, 2H); 2.41 (m, 1H); ^{31}P NMR (D_2O) δ -9.63 (d, J = 21.3), -11.12 (d, J = 21.3 Hz); HRMS-EI found 471.0022 ($M - H^+$)⁻. $C_{13}H_{17}N_2O_{11}P_2S$ requires 471.0035; purity > 97% by HPLC. (System B: 6.9 min).

Diphosphoric acid 1- β -tert-butyl ester 2-(2-thiouridine-5'-yl)ester, ammonium salt (25)

Compound **25** (0.83 mg, 21%) was obtained as a white solid following the general procedure. 1H NMR (D_2O) δ 8.26 (d, J = 8.4 Hz, 1H), 6.68 (d, J = 3.0 Hz, 1H), 6.26 (d, J = 8.1 Hz, 1H), 4.41 (m, 1H), 3.36 (m, 3H), 4.27 (m, 1H), 1.47 (s, 9H); ^{31}P NMR (D_2O) δ -11.00 (d, J = 21.3, Hz), -11.53 (d, J = 21.3 Hz); HRMS-EI found 475.0341 ($M - H^+$)⁻. $C_{13}H_{21}N_2O_{11}P_2S$ requires 475.0341; purity > 98% by HPLC. (System B: 7.16 min).

Preparation of 2-thiouridine-5'- α,β -methylene-diphosphate, triethylammonium salt (11)

A solution of 2-thiouridine (13 mg, 0.05 mmol) and DCC (30mg 0.15 mmol) was stirred in DMF under a nitrogen atmosphere. Methylendiphosphonic acid (13 mg, 0.075 mmol) was added and the stirring was continued for 48 h. The solvent was removed and the product was purified by ion exchange column chromatography with a Sephadex-DEAE A-25 resin, followed by semipreparative HPLC as described above.

Compound **11** (11.8 mg, 33%) was obtained as a white solid. 1H NMR (D_2O) δ 8.22 (d, J = 7.8 Hz, 1H), 6.65 (d, J = 3.2 Hz, 1H), 6.28 (d, J = 7.8 Hz, 1H), 4.47 (m, 2H), 4.37 (m, 2H), 4.26 (m, 1H), 1.47 (t, J = 19.2 Hz, 2H); ^{31}P NMR (D_2O) δ 16.70, 13.32 (m); HRMS-EI found 416.9935 ($M - H^+$)⁻. $C_{10}H_{15}N_2O_{10}P_2S$ requires 416.9923; purity > 98% by HPLC. (System B: 7.04 min).

Assay of P2Y₆ receptor-stimulated PLC activity

Activity at the hP2Y₆ receptor was quantified in 1321N1 human astrocytoma cells stably expressing this receptor. Twenty-four h after plating, the inositol lipid pool of the cells was

radiolabeled by incubation in 200 μL of serum-free inositol-free Dulbecco's modified Eagle's medium, containing 0.4 μCi of *myo*-[^3H]inositol. No changes of medium were made subsequent to the addition of [^3H]inositol. Forty-eight h after transfection, cells were challenged with 50 μL of the five-fold concentrated solution of receptor agonists in 200 mM HEPES, pH 7.3, containing 50 mM LiCl for 20 min at 37 $^\circ\text{C}$. Incubations were terminated by aspiration of the drug-containing medium and addition of 450 μL of ice-cold 50 mM formic acid. After 15 min at 4 $^\circ\text{C}$, samples were neutralized with 150 μL of 150 mM NH_4OH . [^3H] Inositol phosphates were isolated by ion exchange chromatography on Dowex AG 1-X8 columns as previously described.³⁰

Assay of P2Y₁₄ receptor-inhibited accumulation of 3',5'-cyclic adenosine monophosphate (cAMP)

Cell culture: Human embryonic kidney-293 cells stably expressing the hP2Y₁₄-R (P2Y₁₄-HEK293 cells) were generated as previously described by Fricks et al.¹⁶ P2Y₁₄-HEK293 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% Genticin (Gibco), and 1% antibiotic-antimocotic (Gibco) at 37 $^\circ\text{C}$ in a 5% CO₂ environment.

cAMP accumulation: P2Y₁₄-HEK293 cells were grown in 24-well plates and incubated with 1 microCi [^3H]adenine/well in serum-free DMEM for at least 2 h prior to assay. Assays were initiated by addition of HEPES-buffered, serum-free DMEM containing 200 microCi 3-isobutyl-1-methyl-xanthine (IBMX) and 30 μM forskolin, with or without drugs, and incubation continued for 15 min at 37 $^\circ\text{C}$. Incubations were terminated by aspiration of the medium and addition of 450 μL ice-cold 5% trichloroacetic acid. [^3H]cAMP was isolated by sequential Dowex and alumina chromatography and quantified by liquid scintillation counting as previously described by Harden et al. (53).

Data Analysis

Agonist potencies (EC₅₀ values) were obtained from concentration-response curves by non-linear regression analysis using the GraphPad software package Prism (GraphPad, San Diego, CA). All experiments were performed in triplicate assays and repeated at least three times. The results are presented as mean \pm SEM from multiple experiments or in the case of concentration effect curves from a single experiment carried out with triplicate assays that were representative of results from multiple experiments.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Mass spectral measurements were carried out by Dr. John Lloyd and Dr. Noel Whittaker (NIDDK). We thank Dr. Andrei A. Ivanov and Dr. Stefano Costanzi (NIDDK) for helpful discussion and Dr. Sonia de Castro (NIDDK) for technical assistance. This research was supported in part by the Intramural Research Program of the NIH, National Institute of Diabetes and Digestive and Kidney Diseases. This work was supported by National Institutes of Health Grant GM38213 to T.K. Harden.

Abbreviations

cAMP	3',5'-cyclic adenosine monophosphate
CHO	Chinese hamster ovary
DCC	dicyclohexylcarbodiimide


DMEM	Dulbecco's modified Eagle medium
DMF	dimethylformamide
HEK	human embryonic kidney
HEPES	<i>N</i> -2-hydroxyethylpiperazine- <i>N'</i> -2-ethanesulfonic acid
HPLC	high performance liquid chromatography
PLC	phospholipase C
SAR	structure activity relationship
TBAP	tributylammonium phosphate
TEAA	triethylammonium acetate
UDP	uridine-5'-diphosphate
UDPG	uridine-5'-diphosphoglucose

References

1. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Fumagalli M, King BF, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology. Update of the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacol. Rev* 2006;58:281–341. [PubMed: 16968944]
2. Jacobson KA, Jarvis MF, Williams M. Perspective: Purine and pyrimidine (P2) receptors as drug targets. *J. Med. Chem* 2002;45:4057–4093. [PubMed: 12213051]
3. von Kügelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. *Pharmacology Therapeutics* 2006;110:415–432. [PubMed: 16257449]
4. Shaver SR. P2Y receptors: biological advances and therapeutic opportunities. *Curr. Opin. Drug Disc* 2001;4:665–670.
5. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D, Di Virgilio F, Virchow JC Jr, Lambrecht BN. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. *Nature Med* 2007;13:913–919. [PubMed: 17632526]
6. Gachet C. Regulation of platelet functions by P2 receptors. *Ann. Rev. Pharmacol. Toxicol* 2006;46:277–300. [PubMed: 16402906]
7. Shin A, Toy T, Rothenfusser S, Robson N, Vorac J, Dauer M, Stuplich M, Endres S, Cebon J, Maraskovsky E, Schnurr M. P2Y receptor signaling regulates phenotype and IFN- α secretion of human plasmacytoid dendritic cells. *Blood* 2008;111:3062–3069. [PubMed: 17993619]
8. Malin SA, Davis BM, Koerber HR, Reynolds IJ, Albers KM, Molliver DC. Thermal nociception and TRPV1 function are attenuated in mice lacking the nucleotide receptor P2Y₂. *Pain* 2008;138:484–496. [PubMed: 18343036]
9. Lugo-Garcia L, Filhol R, Lajoix AD, Gross R, Petit P, Vignon J. Expression of purinergic P2Y receptor subtypes by INS-1 insulinoma beta-cells: a molecular and binding characterization. *Eur. J. Pharmacol* 2007;568:54–60. [PubMed: 17509560]
10. Lazarowski ER, Tarran R, Grubb BR, van Heusden CA, Okada S, Boucher RC. Nucleotide release provides a mechanism for airway surface liquid homeostasis. *J. Biol. Chem* 2004;279:36855–36864. [PubMed: 15210701]
11. Müller T, Bayer H, Myrtek D, Ferrari D, Sorichter S, Ziegenhagen MW, Zissel G, Virchow JC Jr, Luttmann W, Norgauer J, Di Virgilio F, Idzko M. The P2Y₁₄ receptor of airway epithelial cells coupling to intracellular Ca²⁺ and IL-8 secretion. *Am. J. Respir. Cell. Mol. Biol* 2005;33:601–609. [PubMed: 16109883]

12. Ko H, Fricks I, Ivanov AA, T. Harden TK, Jacobson KA. Structure activity relationship of uridine 5'-diphosphoglucose (UDP-glucose) analogues as agonists of the human P2Y₁₄ receptor. *J. Med. Chem* 2007;50:2030–2039. [PubMed: 17407275]
13. Ko H, Das A, Carter RL, Fricks IP, Zhou Y, Ivanov AA, Melman A, Joshi BV, Kováč P, Hajdúch J, Kirk KL, Harden TK, Jacobson KA. Molecular recognition in the P2Y₁₄ receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose. *Bioorg. Med. Chem* 2009;17:5298–5311. [PubMed: 19502066]
14. Carter RL, Fricks IP, Barrett MO, Burianek LE, Zhou Y, Jacobson KA, Lazarowski ER, Harden TK. Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y₁₄ receptor. *Mol. Pharmacol.* 2009 doi:10.1124/mol.109.058578.
15. Maruoka, H.; Ko, H.; Tosh, DK.; Melman, A.; Carter, R.; Costanzi, S.; Harden, TK.; Jacobson, KA. Selective P2Y₆ receptor agonists: Extended phosphate and (S)-methanocarba ribonucleotide analogs. 238th ACS National Meeting; Washington, DC. Aug. 2009; MEDI187
16. Fricks I, Maddileti S, Carter R, Lazarowski ER, Nicholas RA, Jacobson KA, Harden TK. UDP is a competitive antagonist at the human P2Y₁₄ receptor and a full agonist at the rat P2Y₁₄ receptor. *J. Pharm. Exp. Therap* 2008;325:588–594.
17. Besada P, Shin DH, Costanzi S, Ko H, Mathé C, Gagneron J, Gosselin G, Maddileti S, Harden TK, Jacobson KA. Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y₆ receptor. *J. Med. Chem* 2006;49:5532–5543. [PubMed: 16942026]
18. Ko H, Carter R, Cosyn L, Petrelli R, de Castro S, Besada P, Zhou Y, Cappellacci L, Franchetti P, Grifantini M, Van Calenbergh S, Harden TK, Jacobson KA. Synthesis and potency of novel uracil nucleotide analogues as P2Y₂ and P2Y₆ receptor agonists. *Bioorg. Med. Chem* 2008;16:6319–6332. [PubMed: 18514530]
19. Kim HS, Ravi RG, Marquez VE, Maddileti S, Wihlborg AK, Erlinge D, Malmjö M, Boyer JL, Harden TK, Jacobson KA. Methanocarba modification of uracil and adenine nucleotides: High potency of Northern ring conformation at P2Y₁, P2Y₂, P2Y₄ and P2Y₁₁, but not P2Y₆ receptors. *J. Med. Chem* 2002;45:208–218. [PubMed: 11754592]
20. Ravi RG, Kim HS, Servos J, Zimmermann H, Lee K, Maddileti S, Boyer JL, Harden TK, Jacobson KA. Adenine nucleotide analogues locked in a northern methanocarba conformation: Enhanced stability and potency as P2Y₁ receptor agonists. *J. Med Chem* 2002;45:2090–2100. [PubMed: 11985476]
21. Pascal R, Pirat C, Dueymes C. Facile synthesis of simple mono-alkyl phosphates from phosphoric acid and alcohols. *Tetrahedron Lett* 2008;49:5300–5301.
22. Lazarowski ER, Shea DA, Boucher RC, Harden TK. Release of cellular UDP-glucose as a potential extracellular signaling molecule. *Mol. Pharmacol* 2003;63:1190–1197. [PubMed: 12695547]
23. Harden TK, Hawkins PT, Stephens L, Boyer JL, Downes P. Phosphoinositide hydrolysis by guanosine 5'-[gamma-thio]triphosphate-activated phospholipase C of turkey erythrocyte membranes. *Biochem. J* 1988;252:583–593. [PubMed: 2843174]
24. Boyer JL, Downes CP, Harden TK. Kinetics of activation of phospholipase C by P2Y purinergic receptor agonists and guanine nucleotides. *J. Biol. Chem* 1989;264:884–890. [PubMed: 2910869]
25. Jacobson KA, Ivanov AA, de Castro S, Harden TK, Ko H. Development of selective agonists and antagonists of P2Y receptors. *Purinergic Signalling* 2009;5:75–89. [PubMed: 18600475]
26. Ivanov AA, Fricks I, Harden TK, Jacobson KA. Molecular dynamics simulation of the P2Y₁₄ receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety. *Bioorg. Med. Chem. Lett* 2007;17:761–766. [PubMed: 17088057]
27. Eliahu SE, Camden J, Lecka J, Weisman GA, Sévigny J, Gélinas S, Fischer B. Identification of hydrolytically stable and selective P2Y₁ receptor agonists. *Eur. J. Med. Chem* 2009;44:1525–1536. [PubMed: 18760862]
28. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. *Biochim. Biophys. Acta* 2008;1783:673–694. [PubMed: 18302942]
29. Gendaszewska-Darmach E, Maszewska M, Zakłós M, Koziółkiewicz M. Degradation of extracellular nucleotides and their analogs in HeLa and HUVEC cell cultures. *Acta Biochim. Polonica* 2003;50:973–984.

30. Harden TK, Scheer AG, Smith MM. Differential modification of the interaction of cardiac muscarinic cholinergic and beta-adrenergic receptors with a guanine nucleotide binding component(s). *Mol. Pharmacol* 1982;21:570–580. [PubMed: 6287196]




1 X = O, UDP-glucose
2 X = S, MRS2690

3 X = O, UDP
4 X = S, 2-thio-UDP


Chart 1.

Structures of two UDP-sugars (**1**, **2**) that act as P2Y₁₄ receptor agonists, UDP **3**, a naturally occurring ligand of the hP2Y₁₄ receptor, and its analogue 2-thio-UDP **4**.


**Scheme 1.**

Synthesis of UDPG analogues including UDP β -esters. *Reagents and conditions:* (a) ROPO₃H₂, DMF, rt.


A



B

**Scheme 2.**

A) Synthesis of thio-UMP derivatives **34** and **35**. *Reagents and conditions:* (a) (i) POCl₃, proton sponge, PO(OMe)₃, 0°C (ii) 0.2 M triethylammonium bicarbonate, rt. B) Synthesis of thio-UDP derivatives **15-18**, **21**, and **25**. *Reagents and conditions:* (b) H₃PO₄, Pyridine, Et₃N, Ac₂O (c) (i) CDI, DMF, rt; (ii) 5% TEA in 1/1 MeOH/H₂O; (d) 2-thiouridine-5'-monophosphate tributylammonium salt **34** or 4-thiouridine-5'-monophosphate tributylammonium salt **35**, DMF, rt.

**Scheme 3.**

Synthesis of α,β -methylene-2-thio-UDP **11**. *Reagents and conditions:* (a) DCC, DMF, rt.







Figure 1.



(A) Activation of G_i -coupled $P2Y_{14}$ receptor (left panel) was assessed by quantification of inhibition of forskolin-stimulated $[^3H]$ cyclic AMP accumulation in HEK293 cells stably expressing the h $P2Y_{14}$ receptor. Activation of the G_q -coupled $P2Y_6$ receptor (right panel) was assessed by quantification of $[^3H]$ inositol phosphate accumulation in 1321N1 human astrocytoma cells stably expressing the h $P2Y_6$ receptor by agonists U_{p2} -OMe **14**, 2-thio- U_{p2} -OMe **15**, and its O-propyl ester **18** (B) Activation of G_i -coupled $P2Y_{14}$ receptor (left panel) was assessed by quantification of inhibition of forskolin-stimulated $[^3H]$ cyclic AMP accumulation in HEK293 cells stably expressing the h $P2Y_{14}$ receptor. Activation of the G_q -coupled $P2Y_6$ receptor (right panel) was assessed by quantification of $[^3H]$ inositol phosphate accumulation in 1321N1 human astrocytoma cells stably expressing the h $P2Y_6$ receptor by methylene-bridged agonist **10**, its 2-thio analogue **11**, and the difluoromethylene-bridged agonist **12**.


Table 1

In vitro pharmacological data for UDPG **1**, UDP **3**, and their analogues (nonsugar β -phosphoesters and other derivatives of UDP) in the inhibition of cAMP formation at recombinant hP2Y₁₄ receptors expressed in HEK-293 cells stably transfected with the hP2Y₁₄ and in the stimulation of PLC at recombinant hP2Y₆ receptors stably expressed in 1321N1 cells. Unless noted: X, Y = O, Z = H.


Compound	Modification	Structure R =
UDP-sugars		

Compound	Modification	Structure R =
1	UDP-[1]glucose	 

		
Compound	Modification	Structure R =
2^b	2-thio-UDP-[1]glucose,	
UDP analogues		
3	UDP	HO
4	2-thio-UDP	HO, X ¹ = S
5	4-thio-UDP	HO, X ² = S
6	Up ₂ -β-Me-phosphonate	R = CH ₃




Compound	Modification	Structure R =
7	N^4 -OCH ₃ -CDP	HO, X ² = N-OCH ₃
8d	(N)-methanocarpa UDP (pure enantiomer)	HO
9d	(S)-methanocarpa UDP (pure enantiomer)	HO
10	Up-CH ₂ -p (α,β-methylene UDP)	HO, Y = CH ₂
11	2-thio-Up-CH ₂ -p (α,β-methylene-2-thio-UDP)	HO, Y = CH ₂ , X ¹ = S
12 ^{b,e}	Up-CF ₂ -p (α,β-difluoromethylene UDP)	HO, Y = CF ₂
13	5-I-Up-CF ₂ -p	HO, Y = CF ₂ , Z = I
UDP β-esters		
14	Up ₂ -OMe	CH ₃ O
15	2-thio-Up ₂ -OMe	CH ₃ O, X ¹ = S
16	4-thio-Up ₂ -OMe	CH ₃ O, X ² = S
17	2-thio-Up ₂ -OEt	CH ₃ CH ₂ O, X ¹ = S
18 ^e	2-thio-Up ₂ -OPr	CH ₃ (CH ₂) ₂ O, X ¹ = S
19	Up ₂ -O(CH ₂) ₂ CN	O(CH ₂) ₂ CN
20	Up ₂ -O(CH ₂) ₂ C≡CH	O(CH ₂) ₂ C≡CH
21	2-thio-Up ₂ -O(CH ₂) ₂ C≡CH	O(CH ₂) ₂ C≡CH, X ¹ = S
22	Up ₂ -OCH ₂ CHOHCH ₂ OH	OCH ₂ CH(OH)-CH ₂ OH
23	Up ₂ -OCH(CH ₂ OH) ₂	OCH(CH ₂ OH) ₂
24	Up ₂ -OC(CH ₃) ₃	OC(CH ₃) ₃
25	2-thio-Up ₂ -OC(CH ₃) ₃	OC(CH ₃) ₃ , X ¹ = S

Compound	Modification	Structure R =
26	Up ₂ -O-cyclohexyl	 <p>The chemical structure shows a nucleotide derivative. It consists of a pyrimidine ring with substituents X¹, X², and Z. The ring is attached to a ribose sugar at the C2 position. The ribose sugar is linked to a phosphate group at the C5 position, which is further linked to a cyclohexyl ring. The phosphate group is shown as R-P(=O)(OH)-Y-P(=O)(OH)-O-.</p>

Compound	Modification	Structure R =
27	Up ₂ -OC ₆ H ₅	
28	Up ₂ -OC ₆ H ₄ -4-NO ₂	
29	Up ₂ -OC ₆ H ₄ -3-Cl	
30	Up ₂ -OC ₆ H ₄ -4-OCH ₃	

NE - no effect at 10 μ M.



^a Agonist potencies reflect stimulation of phospholipase C, unless noted, and were calculated using a four-parameter logistic equation and the GraphPad software package (GraphPad, San Diego, CA). EC₅₀ values (mean \pm standard error) represent the concentration at which 50% of the maximal effect is achieved. Relative efficacies (%) were determined by comparison with the effect produced by a maximal effective concentration of reference agonist (UDP-glucose, **1**) in the same experiment. If no maximal effect is given, then 100% efficacy was achieved. N = 3.

^b Potency at P2Y₆ receptor reported in Maruoka et al.,¹⁵ Besada et al.,¹⁷ and Ko et al.¹⁸ Potency at P2Y₁₄ receptor reported in Ko et al.^{12,13}

^c <50% effect at 10 μ M.

^d Structure is given below.

^e12, MRS2802; 18, MRS2907.¹⁴